 Angela Rachubinski
Concepts (122)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Down Syndrome | 21 | 2025 | 469 | 4.080 |
Why?
| | Janus Kinase Inhibitors | 3 | 2024 | 25 | 2.010 |
Why?
| | Piperidines | 3 | 2024 | 190 | 1.810 |
Why?
| | Pyrimidines | 3 | 2024 | 445 | 1.600 |
Why?
| | Neural Stem Cells | 2 | 2012 | 142 | 0.690 |
Why?
| | Chromosomes, Human, Pair 21 | 2 | 2024 | 42 | 0.390 |
Why?
| | tau Proteins | 1 | 2012 | 78 | 0.380 |
Why?
| | Autism Spectrum Disorder | 1 | 2016 | 385 | 0.370 |
Why?
| | Stem Cell Transplantation | 1 | 2012 | 165 | 0.360 |
Why?
| | Autoimmunity | 3 | 2024 | 860 | 0.300 |
Why?
| | Cognition Disorders | 1 | 2012 | 497 | 0.290 |
Why?
| | Heart Defects, Congenital | 2 | 2025 | 740 | 0.280 |
Why?
| | Immunoglobulins | 1 | 2025 | 157 | 0.230 |
Why?
| | Erythropoiesis | 1 | 2024 | 51 | 0.230 |
Why?
| | Cognition | 1 | 2012 | 1107 | 0.230 |
Why?
| | Heme | 1 | 2024 | 76 | 0.220 |
Why?
| | Blood-Brain Barrier | 1 | 2025 | 127 | 0.220 |
Why?
| | Pyrroles | 1 | 2024 | 191 | 0.220 |
Why?
| | Receptors, Interferon | 2 | 2023 | 50 | 0.210 |
Why?
| | Cytokines | 4 | 2024 | 1983 | 0.210 |
Why?
| | Young Adult | 5 | 2025 | 12312 | 0.190 |
Why?
| | Aging | 1 | 2012 | 1750 | 0.190 |
Why?
| | Trisomy | 2 | 2019 | 77 | 0.190 |
Why?
| | Interferon-alpha | 2 | 2019 | 192 | 0.190 |
Why?
| | Arthritis, Psoriatic | 1 | 2021 | 20 | 0.190 |
Why?
| | Adult | 10 | 2025 | 35299 | 0.180 |
Why?
| | Adolescent | 6 | 2025 | 20179 | 0.180 |
Why?
| | Brain | 1 | 2012 | 2620 | 0.170 |
Why?
| | Animals, Newborn | 2 | 2012 | 803 | 0.170 |
Why?
| | Child, Preschool | 5 | 2025 | 10384 | 0.160 |
Why?
| | Kynurenine | 1 | 2019 | 105 | 0.150 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2023 | 508 | 0.150 |
Why?
| | Behavior, Animal | 2 | 2012 | 484 | 0.150 |
Why?
| | Female | 13 | 2025 | 68153 | 0.150 |
Why?
| | Humans | 19 | 2025 | 128417 | 0.150 |
Why?
| | Proteome | 2 | 2024 | 430 | 0.150 |
Why?
| | Hypoxia | 1 | 2024 | 1036 | 0.140 |
Why?
| | T-Lymphocyte Subsets | 1 | 2019 | 409 | 0.140 |
Why?
| | Autoantibodies | 1 | 2024 | 1463 | 0.130 |
Why?
| | Signal Transduction | 3 | 2024 | 4826 | 0.130 |
Why?
| | Male | 9 | 2025 | 62857 | 0.130 |
Why?
| | Child | 6 | 2025 | 20655 | 0.130 |
Why?
| | Case-Control Studies | 4 | 2025 | 3328 | 0.130 |
Why?
| | Disease Models, Animal | 3 | 2023 | 3937 | 0.120 |
Why?
| | Mice | 6 | 2024 | 16602 | 0.120 |
Why?
| | Cell Differentiation | 3 | 2023 | 1900 | 0.110 |
Why?
| | Animals | 8 | 2025 | 34479 | 0.100 |
Why?
| | Infant | 2 | 2024 | 8914 | 0.100 |
Why?
| | Drinking Behavior | 1 | 2012 | 10 | 0.100 |
Why?
| | Dentate Gyrus | 1 | 2012 | 30 | 0.100 |
Why?
| | Cell Size | 1 | 2012 | 87 | 0.100 |
Why?
| | Maze Learning | 1 | 2012 | 93 | 0.100 |
Why?
| | Neuroimmunomodulation | 1 | 2012 | 66 | 0.100 |
Why?
| | 1-Methyl-4-phenylpyridinium | 1 | 2011 | 5 | 0.100 |
Why?
| | Avoidance Learning | 1 | 2012 | 67 | 0.100 |
Why?
| | Interferons | 2 | 2023 | 192 | 0.090 |
Why?
| | Genetic Variation | 1 | 2016 | 933 | 0.090 |
Why?
| | Cell Count | 1 | 2012 | 313 | 0.090 |
Why?
| | NADPH Oxidases | 1 | 2011 | 107 | 0.090 |
Why?
| | Dopaminergic Neurons | 1 | 2011 | 57 | 0.090 |
Why?
| | Green Fluorescent Proteins | 1 | 2012 | 380 | 0.090 |
Why?
| | Analysis of Variance | 1 | 2012 | 1269 | 0.080 |
Why?
| | Cell Survival | 1 | 2012 | 1077 | 0.080 |
Why?
| | Reactive Oxygen Species | 1 | 2011 | 577 | 0.080 |
Why?
| | Middle Aged | 3 | 2025 | 30889 | 0.080 |
Why?
| | Neoplasms | 1 | 2023 | 2464 | 0.070 |
Why?
| | Transcriptome | 2 | 2024 | 881 | 0.070 |
Why?
| | Immunohistochemistry | 1 | 2012 | 1664 | 0.070 |
Why?
| | Proteomics | 2 | 2025 | 1009 | 0.070 |
Why?
| | Hippocampus | 1 | 2012 | 801 | 0.070 |
Why?
| | Mice, Transgenic | 1 | 2012 | 2071 | 0.070 |
Why?
| | Inflammation | 1 | 2017 | 2654 | 0.070 |
Why?
| | Gene Expression Profiling | 2 | 2024 | 1688 | 0.060 |
Why?
| | Cells, Cultured | 1 | 2012 | 4001 | 0.060 |
Why?
| | Erythropoietin | 1 | 2024 | 84 | 0.050 |
Why?
| | Biomarkers | 2 | 2025 | 3880 | 0.050 |
Why?
| | Growth Disorders | 1 | 2022 | 80 | 0.050 |
Why?
| | Gene Silencing | 1 | 2023 | 185 | 0.050 |
Why?
| | Neuroimaging | 1 | 2024 | 278 | 0.050 |
Why?
| | Stress, Physiological | 1 | 2024 | 410 | 0.050 |
Why?
| | Transcriptional Activation | 1 | 2023 | 356 | 0.040 |
Why?
| | Clonal Evolution | 1 | 2021 | 38 | 0.040 |
Why?
| | Cell Line | 2 | 2019 | 2731 | 0.040 |
Why?
| | Insulin-Like Growth Factor I | 1 | 2022 | 307 | 0.040 |
Why?
| | Quinolinic Acid | 1 | 2019 | 8 | 0.040 |
Why?
| | Hematopoiesis | 1 | 2021 | 185 | 0.040 |
Why?
| | Biosynthetic Pathways | 1 | 2019 | 23 | 0.040 |
Why?
| | Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2019 | 52 | 0.040 |
Why?
| | Immunotherapy | 1 | 2024 | 587 | 0.040 |
Why?
| | Biomedical Research | 1 | 2025 | 635 | 0.040 |
Why?
| | Genome-Wide Association Study | 1 | 2025 | 1336 | 0.040 |
Why?
| | Cellular Senescence | 1 | 2019 | 173 | 0.040 |
Why?
| | Receptors, Growth Factor | 1 | 2017 | 46 | 0.040 |
Why?
| | Cell Lineage | 1 | 2019 | 334 | 0.040 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2025 | 2062 | 0.040 |
Why?
| | T-Lymphocytes, Regulatory | 1 | 2019 | 375 | 0.030 |
Why?
| | Genetic Predisposition to Disease | 1 | 2025 | 2264 | 0.030 |
Why?
| | Interferon-gamma | 1 | 2019 | 759 | 0.030 |
Why?
| | Flow Cytometry | 1 | 2019 | 1142 | 0.030 |
Why?
| | Mice, Inbred C57BL | 2 | 2019 | 5272 | 0.030 |
Why?
| | Lymphocyte Activation | 1 | 2019 | 1098 | 0.030 |
Why?
| | Transcription Factors | 1 | 2023 | 1628 | 0.030 |
Why?
| | Phenotype | 1 | 2023 | 3044 | 0.030 |
Why?
| | Complement System Proteins | 1 | 2017 | 307 | 0.030 |
Why?
| | Metabolomics | 1 | 2019 | 599 | 0.030 |
Why?
| | Gene Expression | 1 | 2019 | 1456 | 0.030 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2019 | 846 | 0.030 |
Why?
| | Quality of Life | 1 | 2025 | 2680 | 0.030 |
Why?
| | Prospective Studies | 1 | 2025 | 7036 | 0.030 |
Why?
| | Losartan | 1 | 2011 | 11 | 0.020 |
Why?
| | Herbicides | 1 | 2011 | 22 | 0.020 |
Why?
| | Angiotensin II Type 1 Receptor Blockers | 1 | 2011 | 33 | 0.020 |
Why?
| | Chronic Disease | 1 | 2017 | 1705 | 0.020 |
Why?
| | Electron Transport Complex I | 1 | 2011 | 38 | 0.020 |
Why?
| | Substantia Nigra | 1 | 2011 | 56 | 0.020 |
Why?
| | Risk Factors | 1 | 2025 | 9704 | 0.020 |
Why?
| | Oxidants | 1 | 2011 | 106 | 0.020 |
Why?
| | Protein Subunits | 1 | 2011 | 230 | 0.020 |
Why?
| | Hydrogen Peroxide | 1 | 2011 | 308 | 0.020 |
Why?
| | RNA, Small Interfering | 1 | 2011 | 571 | 0.020 |
Why?
| | Retrospective Studies | 1 | 2024 | 14454 | 0.020 |
Why?
| | Rats | 1 | 2011 | 5165 | 0.010 |
Why?
|
|
Rachubinski's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|